A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
about
Real-time analysis of the effects of toxic, therapeutic and sub-therapeutic concentrations of digitoxin on lung cancer cellsA systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cellsThe steady progress of targeted therapies, promising advances for lung cancerTargeting the Checkpoint to Kill Cancer CellsTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responseCIViC databaseWhole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapySynthetic lethality in lung cancer and translation to clinical therapiesDrugging the addict: non-oncogene addiction as a target for cancer therapyTargeting CDK4 and CDK6: From Discovery to TherapyCyclin D as a therapeutic target in cancerRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Novel insights into the molecular origins and treatment of lung cancerBAY61-3606 affects the viability of colon cancer cells in a genotype-directed mannerCDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction pointComprehensive analysis of high-throughput screens with HiTSeekRSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKTargeting pathways downstream of KRAS in lung adenocarcinoma.Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA deliveryRecent advances of highly selective CDK4/6 inhibitors in breast cancerCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Targeting protein prenylation for cancer therapySystems biology approaches to develop innovative strategies for lung cancer therapy.SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression.Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.Development of small-molecule probes that selectively kill cells induced to express mutant RASPreclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineTwist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.The essence of senescence.Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progressionRequirement for CDK6 in MLL-rearranged acute myeloid leukemia.Development of synthetic lethality anticancer therapeutics.The history and future of targeting cyclin-dependent kinases in cancer therapy.MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cellsTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence.
P2860
Q23919744-D76A3C7B-7369-4E16-B352-66AD7163D52CQ24297823-95D9591B-9E36-463C-95A7-60E190D60877Q26746895-F1EF7E6F-88A5-43A2-82EF-CF99DE38C899Q26795781-C2342D79-0CF0-4FFC-B86A-180FBE958B1FQ26827580-6AE2420D-E2D9-49F6-9111-CE08F14C3A3EQ27014080-3C70E354-C6F1-4CB7-A897-F7310492EE8AQ27612411-D9ECDAB3-6947-40B3-BBC2-D9807A19890FQ27853005-8FAB7752-7C80-488C-8AFB-793F302F3EE7Q27853338-EC989137-E4F3-4429-AD62-1B1D72551EE8Q28069764-5CF45EF2-00F6-427E-A987-C2F76FC5F0BEQ28072904-FC1FF5FC-D1A5-4280-AF06-371C0A8E7CEAQ28079559-7D6414BB-4E4C-455C-9B9E-956146729A16Q28082912-F47F7AF6-3590-4DFF-B76C-8504CCABD3DFQ28242623-413D9B2A-8CA1-45D3-AF22-B0C5BE8F78F3Q28260541-2B0D1F41-727B-49B7-8318-6C47AC7241ECQ28386773-9B732C7E-07E4-48AC-B546-AA1EA5FD3E3CQ28481390-8FBAEEDD-B110-4683-B853-88867608C4E8Q28533417-C207E1B8-4928-4CFC-990E-235A433C9DD2Q28828726-B2752106-A3A2-4D0A-8E7A-64258090ABDEQ28833740-568029A6-D197-4CE7-8773-E6BAE37E2696Q30597330-138F36E0-EB9E-4371-8DFB-0A0568DB1A1EQ33587012-7652CC47-246C-4916-92EC-1DF52AE1E7B0Q33602076-84D9474F-BA15-41C3-9F40-E44496FC0B69Q33614544-F75D3E6E-38FB-4DF4-BC85-3AC1A76FFBB2Q33679239-F4E59292-6787-4A27-AB3B-638C662D667CQ33720233-1AC0DE67-CEB1-4011-8884-19B733D52950Q33876908-1A41C057-DE52-4735-AB6A-1AE03C9FDFD8Q33907588-4930DC4E-753A-4A8E-BEDF-6A028DD376B9Q34148375-194D2496-D2A1-4E4C-ABDA-B23A83CD815AQ34217662-EDE9AF56-A53F-42AD-83A1-5A42C385274DQ34288798-960D5A42-2D98-4271-A45A-DE150A7C8D5BQ34288983-CB3D7E34-242C-476F-8628-5ABFE745DBDEQ34294188-49FC484D-AE93-450F-BC97-F65ADF525F64Q34310186-522E376C-E614-4922-9218-449F58EE6BE1Q34380368-AF79E7C9-D90F-474F-AFE0-C3C2021492FEQ34460347-6AE963CD-D8AC-4C0B-B0C0-D0E76A39887BQ34619148-C5D7E2DD-6322-488B-B704-3397956DA84DQ34659415-017DA134-A8B8-445A-A2E8-8BFB0A824470Q34887604-815F1138-CCD1-44ED-BDFF-565F7560948DQ35007125-437E2B71-147F-430B-8485-64A82B967530
P2860
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@ast
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@en
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@nl
type
label
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@ast
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@en
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@nl
prefLabel
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@ast
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@en
A synthetic lethal interaction ...... non-small cell lung carcinoma.
@nl
P2093
P50
P3181
P1433
P1476
A synthetic lethal interaction ...... non-small cell lung carcinoma
@en
P2093
Alberto Martín
David Santamaría
Mariano Barbacid
Marta Puyol
Pierre Dubus
Pilar Pizcueta
P3181
P356
10.1016/J.CCR.2010.05.025
P577
2010-07-01T00:00:00Z